Acquisitive Valeant takes first bite at dental market with $312m OraPharma buy
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals International's latest company buy-out sees the acquisitive Canadian firm enter the dental segment of the healthcare market for the first time. Valeant views the dental market as having similar characteristics to speciality markets like dermatology and ophthalmology, in which it already has a presence. It also sees the opportunity for cross-selling some of its current products, such as the cold sore treatment Xerese (aciclovir plus hydrocortisone) that it acquired from Meda last year (scripintelligence.com, 30 June 2011).